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Abstract
Interstitial cystitis is a serious chronic condition that causes bladder pain and
increased voiding frequency in millions of adults in the US, most of them women. A
possible biomarker that may be linked to bladder inflammation is the CXCL chemokine
family, specifically CXCL9, CXCL10, and CXCL11. The goal of this project is to
investigate the expression and regulation of these CXCL chemokines during acute and
chronic inflammation of the urinary bladder. Wild-type C57BL/6J mice were injected
with cyclophosphamide (CYP) to induce bladder inflammation. RT-PCR and ELISAs
were used to determine mRNA and protein expression of CXCL9, CXCL10, and
CXCL11 chemokines. During CYP-induced cystitis, the detrusor muscle exhibited more
CXCL mRNA regulation in both males and females compared to the urothelium. CYPinduced cystitis significantly (p ≤ 0.05) upregulated CXCL10, while CXCL9 and
CXCL11 were significantly (p ≤ 0.05) downregulated. CXCL chemokines were also
more regulated during acute and intermediate inflammation versus chronic inflammation.
Females had significantly (p ≤ 0.05) decreased CXCL9 and CXCL11 protein levels after
chronic inflammation. There were no statistical differences between CXCL chemokine
protein levels in males. Future research such as immunohistochemistry to focus on tissue
distribution of chemokines and use of chemokine receptor antagonist should be
performed to further explore the functional role of these chemokines in male and female
urinary bladders.

Introduction
Interstitial cystitis (IC), also known as Painful Bladder Syndrome (PBS), is a
chronic condition that causes bladder pain, discomfort, and urinary urgency in as many as
7.9 million US adult women (1). The prevalence of IC is very disproportionate; many
studies on the topic have discovered a 5:1 ratio of women to men with IC. While IC is
not necessarily life-threatening, the chronic pain it causes can lead to a severely
decreased quality of life equivalent to rheumatoid arthritis, another debilitating chronic
condition (6). The cause of IC is uncertain since there are many different factors that
could work in tandem to cause disease (9). However, it has been discovered that many
IC patients have some form of defect in the urothelium, the tissue that lines the interior of
the bladder (Figure 1), and it is theorized that chemicals in the urine can leak through the
urothelium to cause pain and inflammation (8).
The resulting inflammation has been attributed to a variety of signaling
molecules, including the CXCL chemokine family. Chemokines are a group of small
cytokines that are characterized by their ability to induce chemotaxis in cells. The two
groups of chemokines are homeostatic and inflammatory, though some chemokines can
be both types. Homeostatic chemokines migrate leukocytes such as lymphocytes to
locations in the body by using concentration gradients (12). As their name suggests, they
are responsible for maintaining a homeostatic concentration of leukocytes. Inflammatory
chemokines are activated during infection or other conditions where inflammation is
necessitated and result in the migration of immune cells to their destination. An example
of an inflammatory chemokine is the CXCL chemokine family.

CXCL chemokines are named for their C-X-C amino acid motif, as their Nterminus contains two cysteine residues separated by another amino acid designated as
“X.” The CXCL chemokine family plays several roles throughout the human body, but
CXCL9, CXCL10, CXCL11, and their receptor CXCR3 have been found to play a
significant role in inflammation including in the bladder (13). Their pro-inflammatory
properties play a role in the mediation of angiostasis (4) but can also impair bladder
function, leading to conditions such as IC (7). Some studies have been conducted on
CXCL9, CXCL10, and CXCL11 and their general response to inflammation (11) but not
on the specifics of location of activity and expression. The goal of this project is to
determine the expression and regulation of these CXCL chemokines in cystitis in male
and female mice, the mRNA and protein levels in the urothelium and detrusor muscle,
and the effect of varying duration of bladder inflammation on CXCL regulation in
urinary bladder inflammation. Learning more about the expression and regulation of
CXCL chemokines in the bladder with cystitis may eventually be translated into a future
treatment for human cystitis or biomarker for the disease.
Materials and Methods
The mice used in this study were wild-type (WT) C57BL/6J mice and were bred
at the Larner College of Medicine at The University of Vermont. All experimental
protocols involving animal use were approved by the UVM Institutional Animal Care and
Use Committee (IACUC #08-085 and #14-060). Animal care was under the supervision
of the UVM Office of Animal Care Management with the Association for Assessment
and Accreditation of Laboratory Care and National Institutes of Health guidelines. All
efforts were made to minimize the potential for animal pain, stress, or distress.

Both male and female adult (3-4 months) mice (n = 6-7) were subjected to
cyclophosphamide (CYP) injections administered intraperitoneally to stimulate urinary
bladder inflammation. Cyclophosphamide is metabolized by the body into acrolein,
which builds up in the urinary bladder and irritates the urothelium to cause inflammation.
The groups were differentiated based on whether the inflammation was acute or chronic
and on the gender of the mice. The acute groups consisted of mice treated with one CYP
treatment (200 mg/mL per kg mouse), whereas the chronic group received a CYP
treatment (75 mg/mL per kg mouse) every three days for a total of three treatments. The
control group received no CYP treatments. Previous studies have demonstrated no
differences in inflammatory mediators when rodents receive saline injections compared
to no treatment. The mice were deeply anesthetized with isoflurane (5%) and then
euthanized via thoracotomy. Bladders were harvested from the acute inflammation group
either 4 hours (acute inflammation) or 48 hours (intermediate inflammation) after CYP
treatment. Bladders were harvested from the chronic inflammation group 10 days after
CYP treatment. The L6 and S1 sections of the spinal cord and dorsal root ganglia were
also harvested for future analysis of CXCL transcript levels. The urinary bladder and
lumbosacral (L6-S1) dorsal root ganglia were quickly dissected under RNase-free
conditions. For mRNA analysis, the bladder was cut open along the midline and pinned
to a sylgard-coated dish and the urothelium and suburothelium were removed from the
detrusor muscle with the aid of fine forceps and a dissecting microscope. In this study,
the use of the term urothelium refers to the urothelium and suburothelial layers. For
protein analysis, the bladders were kept whole rather than being separated into

urothelium and detrusor components due to time constraints. All tissues were snapfrozen on dry ice prior to processing.
Quantitative RT-PCR was used to determine CXCL9, CXCL10, and CXCL11
mRNA transcript levels in the urothelium and in the detrusor muscle. Total RNA was
extracted using STAT-60 total RNA/mRNA isolation (Tel-Test ‘B’, Friendswood, TX,
USA). One microgram of RNA per sample was used to synthesize complementary DNA
using a mix of random hexamer and oligo dT primers with M-MLV reverse transcriptase
(Promega Corp., Madison, WI, USA) in a 25-uL final reaction volume. The quantitative
PCR standards for all transcripts were prepared with the amplified cDNA products
ligated directly into pCR2.1 TOPO vector using the TOPO TA cloning kit (Invitrogen,
Carlsbad, CA, USA). The nucleotide sequences of the inserts were verified by automated
fluorescent dideoxy dye terminator sequencing (Vermont Cancer Center DNA Analysis
Facility). To estimate the relative expression of the receptor transcripts, 10-fold serial
dilutions of stock plasmids were prepared as quantitative standards. The range of
standard concentrations was determined empirically. Complementary DNA templates,
diluted 10-fold to minimize the inhibitory effects of the reverse transcription reaction
components, were assayed using HotStart-IT SYBR Green qPCR Master Mix (USB,
Cleveland, OH, USA) and 300 nM of each primer in a final 25-µL reaction volume.
Real-time quantitative PCR was performed on an Applied Biosystems 7500 Fast realtime PCR system (Applied Biosystems, Foster City, CA, USA) using the following
standard conditions: (1) serial heating at 94 °C for 2 minutes and (2) amplification over
45 cycles at 94 °C for 15 seconds and 60°C for 30 seconds. The amplified product from
these amplification parameters was subjected to SYBR Green I melting analysis by

ramping the temperature of the reaction samples from 60 to 95 °C. A single DNA melting
profile was observed under these dissociation assay conditions demonstrating the
amplification of a single unique product free of primer dimers or other anomalous
products. Oligonucleotide primer sequences were: CXCL9: upper primer (5'GTGGAGTTCGAGGAACCCTAG-3'); lower primer (5'ATTGGGGCTTGGGGCAAAC-3'); CXCL10: upper primer (5'GTGGGACTCAAGGGATCCCTC-3'); lower primer (5'CAGGATAGGCTCGCAGGGATG-3'); CXCL11: upper primer (5'GCTCAAGGCTTCCTTATGTTCAAAC-3'); lower primer (5'CTTTGTCGCAGCCGTTACTCG-3')
For data analyses, a standard curve was constructed by amplification of serially
diluted plasmids containing the target sequence. Data were analyzed at the termination of
each assay using sequence detection software (Sequence Detection Software, version
1.3.1; Applied Biosystems, Norwalk, CT, USA). In standard assays, default baseline
settings were selected. The increase in SYBR Green I fluorescence intensity (ΔRn) was
plotted as a function of cycle number, and the threshold cycle was determined by the
software as the amplification cycle at which the ΔRn first intersects the established
baseline. All data are expressed as the relative quantity of the gene of interest normalized
to the relative quantity of the housekeeping gene ribosomal protein L32.
ELISAs were used to determine CXCL9, CXCL10, and CXCL11 content in the
urinary bladder of mice (n = 6–7) with and without CYP treatment. Whole urinary
bladders were homogenized separately in tissue protein extraction agent (T-PER; Roche,
Indianapolis, IN), a commercially available, mild zwitterionic dialyzable detergent in

25 mM bicine, 150 mM sodium chloride (pH 7.6) containing a protease inhibitor mix
(Sigma-Aldrich, St. Louis, MO; 16 μg/ml benzamidine, 2 μg/ml leupeptin, 50 μg/ml lima
bean trypsin inhibitor, and 2 μg/ml pepstatin A), and aliquots were removed for protein
assay. The supernatants were used for quantification. Total protein was determined with
the Coomassie Plus (Bradford) Protein Assay Kit (Fisher Scientific, Pittsburgh, PA).
According to the manufacturer (R&D Systems, Minneapolis, MN), the CXCL9,
CXCL10, and CXCL11 DuoSets do not show cross-reactivity or interference with similar
recombinant human and mouse proteins at concentrations up to 50 ng/ml. The standards
provided with these systems generated linear standard curves (R2 = 0.985–0.998,
p ≤ 0.001). Absorbance values of standards and samples were corrected by subtraction of
the background value (absorbance due to nonspecific binding). No samples fell below the
detection limits of the assays, and samples were not diluted before assay. Curve fitting of
standards and evaluation of CXCL9, CXCL10, and CXCL11 content of samples were
performed with a least-squares fit.
All values were expressed as means ± S.E.M. Comparisons among experimental
groups were made using one-way analysis of variance (ANOVA). Animals, processed
and analyzed on the same day, were tested as a block in the ANOVA. Outliers
determined by using a Q test were removed from analysis. When F ratios exceeded the
critical value (p ≤ 0.05), Tukey’s multiple comparison test was used to compare
experimental means among groups.
Results
Male mice exhibited no significant changes in CXCL9 or CXCL10 mRNA levels
in the urothelium when experimental groups were compared to the control (Figure 2).

However, there was a significant (p = 0.0035 for acute, p = 0.0013 for intermediate, p <
0.0001) downregulation of CXCL11 in the male urothelium in all CYP treatment groups.
Female mice exhibited significant upregulation in CXCL10 in the urothelium for the
acute (4 hour) and intermediate (48 hour) groups (p = 0.0003 for acute, p = 0.0266 for
intermediate) and CXCL11 in the urothelium for the acute group (p = 0.0009) (Figure 3).
CXCL9 was significantly downregulated in male detrusor muscle for all inflammatory
groups (p < 0.0001 for acute, p = 0.0002 for intermediate, p < 0.0001 for chronic) but
was not significantly regulated in females. CXCL10 was significantly upregulated in
male detrusor muscle in the acute and intermediate groups (p = 0.0099 for acute, p =
0.0472 for intermediate) and significantly upregulated in female detrusor muscle in the
acute and chronic groups (p = 0.0006 for acute, p = 0.0259 for chronic). CXCL11 was
significantly downregulated in male detrusor muscle in the acute and chronic groups (p =
0.0032 for acute, p = 0.0032 for chronic) and in the female detrusor intermediate group (p
= 0.0092 for intermediate).
Urinary bladders of female mice exhibited significantly decreased protein levels
of CXCL9 and CXCL11 in the chronic inflammation group when compared to the
control (p = 0.0242 for CXCL9 chronic, p = 0.0498 for CXCL11 chronic) (Figure 4). No
significant differences were found in the protein levels of CXCL9, CXCL10, and
CXCL11 in male mice with CYP-induced cystitis.
Discussion
This study produced several interesting findings. First, CXCL10 mRNA was
found to be upregulated during urinary bladder inflammation, whereas CXCL9 and
CXCL10 mRNA were almost always downregulated instead. The detrusor muscle was

also found to be more susceptible to CXCL mRNA regulation than the urothelium with
CYP-induced cystitis. Acute and intermediate bladder inflammation led to more CXCL
mRNA regulation than chronic inflammation. Similar to the downregulation of CXCL9
and CXCL11 mRNA, CXCL9 and CXCL11 protein levels were also decreased during
chronic inflammation in females. No other changes in CXCL protein levels were
demonstrated in either males or females with CYP-induced cystitis.
The upregulation of CXCL11 mRNA in the female urothelium was opposite to
that of the downregulation of CXCL11 mRNA in the male urothelium. In addition,
CXCL10 mRNA was significantly upregulated in all groups when compared to the
control. However, CXCL9 and CXCL11 mRNA were almost always downregulated
except for CXCL11 in the female urothelium. This suggests that the inflammatory
pathway in males and females may be regulated differently with regards to CXCL mRNA
and that CXCL10 may be mechanistically different from CXCL9 and CXCL11 in the
pro-inflammatory pathway in the bladder. CXCL9, CXCL10, and CXCL11 all share
common transcription factors such as NF-κB, STAT1, and IFN regulatory factor (IRF)-1
(2, 13), though they each have specific factors as well. However, it is unknown how
CXCL9, CXCL10, and CXCL11 are specifically regulated in the bladder with regards to
transcription. Future research should be conducted to study the pathway in the bladder.
With CYP-induced cystitis, the detrusor muscle was more susceptible to
regulation of CXCL mRNA than the urothelium in both males and females, indicating
significant regulation of CXCL mRNA does occur in the detrusor muscle. The
urothelium was expected to exhibit regulation of CXCL chemokines because CYP causes
inflammation in the urothelium characterized by urothelial erosion and infiltration of

inflammatory cells. However, inflammatory cell infiltrates are observed throughout the
detrusor muscle as well suggesting that it may be more vulnerable to CYP and
subsequent inflammation.
Acute and intermediate inflammation led to more regulation of CXCL mRNA
compared to chronic inflammation. This may mean CXCL mRNA is more regulated
during the early stages of inflammation. Inflammation is a complex and multi-stage
process so certain mRNA may be activated and deactivated earlier than other transcripts,
and CXCL may be part of the early response rather than later.
Most CXCL protein levels were not significantly different when compared to the
control, which conflicts with the mRNA expression levels. However, CXCL9 and
CXCL11 protein levels were significantly decreased in the female chronic inflammation
group. Again, this means CXCL9 and CXCL11 could play a role as early response
proteins and then be downregulated as inflammation progresses. No other CYP treatment
in males or females exhibited significant differences.
Based on the mRNA expression levels, one might expect some statistical
significance to be present in the ELISA results. Although whole bladders were used and
no bladders separated into urothelium and detrusor, the detrusor muscle accounts for
most of the bladder mass, so CXCL levels should be skewed towards the level of activity
in the detrusor muscle. The lack of variance may indicate that the CXCL mRNA
transcripts are unstable or post-translationally processed in some way that leads to
decreased protein expression. CXCL chemokines might also not remain in the bladder
due to limited storage during inflammation. Chemokine half-lives have been found to be
around 2 hours in blood plasma (3), but it is unknown how stable they are in urinary

bladder tissue. Further research should be conducted to determine exactly how CXCL
mRNA or protein is processed during inflammation.
Interestingly, when comparing the male and female ELISA results, it appears that
CXCL chemokine levels are higher in females compared to males, especially CXCL10.
However, the male and female data cannot be statistically compared to each other
because samples were not run on the same ELISA plates. This is another potential
experiment to perform in the future.
As mentioned previously, the ELISAs were performed using whole bladders
rather than the urothelium and detrusor muscle separately due to low protein yield and the
difficulty in analyzing low protein content in the urothelium and detrusor muscle.
Regardless, in the future, ELISAs should be repeated with split bladders to accurately
compare to the mRNA expression results.
Immunohistochemistry and cystometry with chemokine receptor antagonist
treatment were planned after RT-PCR and ELISAs. Unfortunately, there was not enough
time to pursue those morphological and functional studies. These procedures should be
performed in the future to further explore the role of these CXCLs in the bladder function
during urinary bladder inflammation. For instance, since more regulation is present in
the detrusor muscle, immunohistochemistry should help to determine the level of
expression of each CXCL chemokine in detrusor muscle compared to urothelial cells.
Cystometry would also help to determine if administering a chemokine receptor
antagonist to block the CXCL receptor, CXCR3, would improve voiding outcomes (e.g.,
reduce voiding frequency) in mice with CYP-induced cystitis. Both

immunohistochemistry and chemokine receptor antagonist treatment will give us a better
picture of the expression and possible function of CXCL chemokines in the bladder.
Additional studies should be conducted to better understand the inflammation
pathway in the bladder activated by CYP treatment. This means learning more about the
protein-protein interactions of CXCL9, CXCL10, CXCL10, and CXCR3, the
activation/deactivation of specific proteins, the downstream signaling molecules, and the
aforementioned processing of CXCL transcript and proteins.
A limitation in this study may be the male CXCL ELISA results. There were no
statistical differences between the control and experimental groups for CXCL9, CXCL10,
and CXCL11. The results yielded only a slight, non-significant regression as
inflammation progressed. Although the bladders appeared to be inflamed based on past
gross appearances during bladder extractions, there is still the possibility of some
procedural error or defective cyclophosphamide. The ELISAs should be repeated for the
males to replicate the results.
One possible alternative is the usage of a different normalizer other than or in
addition to ribosomal protein L32. We were only able to test two normalizers, 18S and
L32. Both genes yielded slight regulation despite being housekeeping genes, so testing
other normalizers or using a combination of housekeeping genes could result in better
correction of mRNA variance and more accurate statistical significance.
The results of this experiment were unexpected, as most regulation of the CXCL
chemokines during inflammation occurred in the detrusor muscle rather than the
urothelium. It was also interesting that only CXCL10 was upregulated, and CXCL9 and
CXCL11 were downregulated. Further procedures and research are necessitated to delve

further into the role of these CXCL chemokines in urinary bladder inflammation, such as
using split bladders for ELISAs, immunohistochemistry to confirm location and activity
of CXCL chemokines in bladder cells, and antagonist treatment to determine potential
benefits of CXCR3 blockade.

Figures

Figure 1. Anatomical components of the urinary bladder wall (5). Many receptors
(including CXCR3, the receptor for CXCL chemokines) and ion channels (transient
receptor potential channels) are expressed by the anatomical components of the urinary
bladder wall including the urothelium, bladder sensory nerves, interstitial cells of Cajal
(ICC), and detrusor smooth muscle. The tissues of interest in this study are the
urothelium and detrusor muscle.
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Figure 2. Mean CXCL mRNA levels (fold change) of female mouse urothelium (top)
and detrusor muscle (bottom) with CYP treatment (4 hours, 48 hours, chronic). Groups
that are statistically significant when compared to the control are marked with an asterisk
(Tukey’s multiple comparison test, p ≤ 0.05). n = 6 for all groups.
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Figure 3. Mean CXCL mRNA levels (fold change) of male mouse urothelium (top) and
detrusor muscle (bottom) with CYP treatment (4 hours, 48 hours, chronic). Groups that
are statistically significant when compared to the control are marked with an asterisk
(Tukey’s multiple comparison test, p ≤ 0.05). n = 6 for control, 4 hour, and 48 hour CYP
treatment groups. n = 7 for chronic CYP treatment group.
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Figure 4. Mean CXCL protein level per total protein of female (top) and male (bottom)
mouse bladders with CYP treatment (4 hours, 48 hours, chronic). Groups that are
statistically significant when compared to the control are marked with an asterisk
(Tukey’s multiple comparison test, p ≤ 0.05). n = 6 for all groups.
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